Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.

For prostate cancer radiation therapy, daily sessions spanning approximately 2 months has been considered the standard of care for patients managed with curative intent. In recent years, data has emerged which supports the use of higher dose per fraction schemes leading to a reduced duration of treatment. This form of radiation-generally termed moderate hypofractionation or stereotactic body radiation therapy-increasingly appears to be a safe and effective alternative to the conventional course. This review summarizes salient data from the literature on outcomes, toxicities, and future directions for this innovative strategy of care.

Urologic oncology. 2019 Feb 06 [Epub ahead of print]

Jason M Beckta, Jason D Nosrati, James B Yu

Therapeutic Radiology, Yale University School of Medicine, New Haven, CT., Michigan State University College of Human Medicine, East Lansing, MI., Therapeutic Radiology, Yale University School of Medicine, New Haven, CT. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe